Name: 글로벌 시장 동향
SKU: PH7308
Availability: InStock

보고서 요약(국문)

개요
전 세계 한랭응집소 질환 치료 시장은 2022년 YY억 달러에 달했으며, 2023년부터 2030년까지 연평균 성장률(CAGR) YY%로 성장하여 2030년에는 YY억 달러에 이를 것으로 예상됩니다.
전 세계 한랭응집소 질환 치료 시장은 여러 요인의 영향으로 상당한 성장과 변화를 보여왔습니다. 한랭응집소 질환은 추위에 반응하는 자가항체에 의해 발생하는 드문 자가면역 용혈성 빈혈의 일종입니다.
특히 개발도상국을 중심으로 한 정부 투자와 연구는 첨단 치료법의 활용을 촉진하고 전 세계 한랭응집소 질환 치료 시장 성장을 견인할 것입니다. 이러한 혁신적인 치료법에는 더 나은 치료 효과를 위한 단클론 항체 사용이 포함됩니다.
시장 동향: 성장 요인
신약 또는 치료법의 개발 증가
선진국들은 높은 소득 수준, 투자 및 인프라 개발에 힘입어 의료 부문에서 빠른 성장을 경험하고 있습니다. 여러 국가에서 임상 시험에서 긍정적인 결과가 나오면서 한랭응집소병 치료제에 대한 수요가 크게 증가했으며, 이는 신약 승인으로 이어져 시장 성장을 견인하는 중요한 요인이 될 것입니다.
2023년 7월 7일, 사노피의 임상시험용 약물 SAR445088은 한랭응집소병(CAD) 세포 모델에서 적혈구 손상을 최소화하는 효과를 보이며, 한랭응집소병과 관련된 면역 체계 구성 요소인 보체 경로를 성공적으로 억제하는 것으로 연구 결과가 발표되었습니다. 보다 집중적인 작용 기전 덕분에 SAR445088은 사노피의 엔자이모(수티믈리맙-조메)를 대체할 가능성이 있습니다. 유럽에서는 성인 한랭응집소병 환자를 대상으로 차세대 치료제인 SAR445088의 1상 임상시험(NCT04802057)이 진행 중입니다. 한랭응집소병에 대한 인식이 높아지고 3상 임상시험 단계에 있는 신약 파이프라인이 탄탄해짐에 따라, 한랭응집소병 치료제 시장 성장이 더욱 가속화될 것으로 예상됩니다.

시장 동향: 제약 요인
약물 관련 부작용
증상성 빈혈이나 기타 불편한 증상을 보이는 환자는 치료를 받아야 하지만, 항상 약물 치료가 필요한 것은 아닙니다. 코르티코스테로이드는 부작용 때문에 관상동맥질환(CAD) 치료에는 권장되지 않습니다. 이 약물은 부정맥, 심근경색, 심인성 쇼크와 같은 심장 또는 심장 박동 문제를 유발할 수 있습니다. 단클론항체(mAb) 투여 시 혈청병, 급성 아나필락시스, 항체 생성과 같은 면역 반응이 발생할 가능성이 있습니다.
이 보고서에 대한 자세한 내용은 샘플을 요청하십시오.
세그먼트 분석
전 세계 한랭응집소질환 치료 시장은 유형, 약물 유형, 투여 경로, 유통 채널 및 지역별로 세분화됩니다.
생물학적 제제 부문은 시장 점유율의 약 37%를 차지합니다.
생물학적 제제 부문은 높은 효능과 활발한 연구 및 제품 개발 덕분에 모든 약물 유형 중 가장 큰 시장 점유율을 차지하고 있습니다. 단클론 항체, 면역 조절제, 성장 인자, 백신, 그리고 사람 혈액 및 혈장으로 만든 제품들은 모두 생물학적 의약품이라는 광범위한 범주에 속합니다.
단클론 항체인 리툭시맙은 한랭응집소병의 1차 및 2차 치료제이며, 스테로이드 불응성 온성 자가면역 용혈성 빈혈(wAIHA)의 선호되는 치료제입니다.
시장 점유율
북미는 2022년 시장 점유율의 약 33%를 차지했습니다.
의료 분야에서 한랭응집소병 치료에 대한 수요가 증가함에 따라 북미 제조업체들은 사업 확장의 기회를 얻고 있습니다. 북미에는 많은 생산자와 공급업체가 있으며, 이 지역의 빠른 경제 성장으로 인해 산업 생산이 확대되어 한랭응집소병 치료에 대한 수요를 견인하고 있습니다.

의료비 지출 증가, 연구 활동 확대, 기술 발전 및 다양한 치료제 개발, 그리고 이 지역 전반에 걸친 제약 및 바이오테크 기업 설립 증가는 이 지역의 한랭응집소병 치료 시장 점유율 성장에 기여하고 있습니다. 단일클론 항체와 같은 다양한 신규 치료법에 대한 인식이 높아짐에 따라 이 시장은 성장하고 있습니다. 앞서 언급한 요소들은 북미가 세계에서 차지하는 지배적인 위치를 더욱 뒷받침합니다.
북미는 미국을 중심으로 전 세계 한랭응집소병 치료 시장에서 핵심적인 역할을 계속하고 있습니다. 인프라 개발 및 투자를 장려하는 정부 정책과 기술 발전에 대한 집중적인 투자는 미국 내 한랭응집소병 치료제 수요를 촉진했습니다. 미국은 여러 정책 및 연구를 적극적으로 추진하여 한랭응집소병 치료제 수요를 자극해 왔습니다.
COVID-19 영향 분석
2019년 말 발생한 COVID-19 팬데믹은 전 세계 산업, 특히 전 세계 한랭응집소병 치료 시장에 전례 없는 어려움을 초래했습니다. 각국이 봉쇄 조치, 공급망 차질, 경제 활동 감소에 직면하면서 다양한 종류의 의약품을 주요 소비하는 제약 부문은 상당한 타격을 입었습니다. 2020년 초부터 시작된 팬데믹의 광범위한 봉쇄와 제한 조치로 인해 전 세계적으로 여러 노력이 영향을 받았습니다.
주요 제약 회사들은 생산을 중단하고 코로나19 관리에 집중하면서 한랭응집소병 치료제 수요가 급감했습니다. 하지만 현재 여러 연구가 재개되었고, 기업들은 각자의 파이프라인에 대한 임상 시험을 다시 시작했습니다. 전반적으로, 전 세계 한랭응집소병 치료제 시장에 대한 팬데믹의 영향은 비교적 완만할 것으로 예상되며, 단일클론 항체 및 이와 유사한 질환을 제어하기 위한 기타 프로그램에 대한 지속적인 수요와 연구로 인해 시장은 꾸준히 성장할 것으로 전망됩니다.

주요 동향
• 2022년 2월 4일, 엔자이모(수티믈리맙-좀)가 용혈성 한랭응집소병(CAD) 성인 환자의 적혈구 수혈 필요량을 줄이는 데 FDA 승인을 받았습니다. FDA 승인을 받은 최초이자 유일한 CAD 치료제인 엔자이모는 적혈구 파괴(용혈)를 예방합니다.
경쟁 환경
주요 글로벌 시장 참여 기업으로는 사노피, 노벨메드, 노바티스, 스웨디시 오르판 비오비트룸, 아펠리스 파마슈티컬스, 알파인 이뮨 사이언스, 제넨텍 USA, 알렉시온 파마슈티컬스, 테바 USA, 비아트리스 등이 있습니다.
보고서 구매 이유

• 유형, 약물 유형, 투여 경로, 유통 채널 및 지역별 글로벌 한랭응집소병 치료 시장 세분화를 시각화하고 주요 기업 및 시장 참여자를 파악하기 위함입니다.

• 트렌드 분석 및 공동 개발을 통해 상업적 기회를 파악합니다.

• 모든 세그먼트를 포함한 한랭응집소병 치료제 시장 수준의 다양한 데이터가 담긴 엑셀 데이터 시트를 제공합니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 종합적인 분석 결과를 담은 PDF 보고서를 제공합니다.

• 주요 업체들의 핵심 제품을 모두 포함한 제품 맵핑 자료를 엑셀 파일로 제공합니다.

글로벌 한랭응집소병 치료제 시장 보고서는 약 69개의 표, 68개의 그림, 186페이지 분량입니다.
주요 고객 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자은행
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global cold agglutinin disease treatment market reached US$ YY billion in 2022 and is expected to reach US$ YY billion by 2030, growing with a CAGR of YY% during the forecast period 2023-2030.
The global cold agglutinin disease treatment market has witnessed significant growth and transformations over the years, with various factors influencing its dynamics. A uncommon kind of autoimmune hemolytic anemia is known as cold agglutinin disease, which is brought on by autoantibodies that react to cold.
Government investments and research, particularly in developing economies, will continue to drive utilization of advanced treatments and boost the global cold agglutinin disease treatment market. The respective innovative treatments includes the use of monoclonal antibodies for better treatment.
Market Dynamics: Drivers
Growing development of novel therapies or drugs
Developed economies have been witnessing rapid growth in betterment of their healthcare sectors, driven by high income levels, investments and infrastructure development. Several countries have experienced substantial demand for cold agglutinin disease treatment owing to its positive outcomes in clinical trials leading to drug approval will be a crucial factor driving the growth of the market.
On July 7, 2023, with less red blood cell damage in a cellular model of CAD, Sanofi's investigational medication SAR445088 successfully inhibits the traditional complement pathway, a component of the immune system linked to cold agglutinin disease (CAD) in a study. Because of its more focused activity, SAR445088 might replace Sanofi's Enjaymo (sutimlimab-jome). Adults with CAD are being investigated with the next-generation treatment in a Phase 1 clinical trial in Europe (NCT04802057). Rising awareness among people and increasing robust pipeline with drugs in phase 3 will be a major factor driving the growth of the cold agglutinin syndrome drugs market.
Market Dynamics: Restraints
Side effects associated with the drugs
Patients having symptomatic anemia or other annoying symptoms should be addressed, while medication is not always necessary. Due to their negative effects, corticosteroids are not recommended to treat CAD. Heart or heart rhythm issues, such as arrhythmia, heart attacks, and cardiogenic shock, could be brought on by this medication. When mAbs are administered, there is a chance of immunological reactions like serum sickness, acute anaphylaxis, and the production of antibodies.
For more details on this report - Request for Sample
Segment Analysis
The global cold agglutinin disease treatment market is segmented based on type, drug type, route of administration, distribution channel and region.
Biologics segment holds approximately 37% of market share
The biologics segment from drug type is the largest share holder among all the drug types owing to its high effectiveness and rising researches and product developments. Monoclonal antibodies, immune modulators, growth factors, vaccinations, and items made from human blood and plasma all fall within the broad category of biological medicines.
Rituximab, a monoclonal antibody, is the first- and second-line treatment for cold agglutinin illness as well as the preferred therapy for steroid-refractory warm autoimmune hemolytic anemia (wAIHA).
Geographical Penetration
North America accounted for around 33% of market share in 2022
Due to the rising need for cold agglutinin disease treatment in healthcare, manufacturers in North America have chances of increasing their operations. There are many producers and suppliers in North America and owing to the quick economic growth of the region, industrial production has expanded, driving the demand for cold agglutinin disease treatment.
Increasing expenditure on healthcare and rising research studies, advancement of technologies and different type of drugs for treatment, and increase in pharmaceutical or biotech business establishment across the region are also contributing to the growth of cold agglutinin disease treatment market share of this region. The market in this area is growing as people become more aware of various novel treatments such as monoclonal antibodies. The aforementioned elements further attest to North America's hegemonic position in the world.
North America continues to be a key player in the global cold agglutinin disease treatment market, with United States leading the way. Government initiatives promoting infrastructure development and investment, and a focus on rising advancements have fueled the demand for cold agglutinin disease treatment in the U.S. United States have been proactive in executing several initiatives or researches, stimulating cold agglutinin disease treatment drugs demand.
COVID-19 Impact Analysis
The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global cold agglutinin disease treatment market. As countries grappled with lockdowns, supply chain disruptions and reduced economic activity, the pharmaceutical sector, with a significant consumer of various types of drugs, was significantly impacted. Several efforts all throughout the world were impacted by the pandemic's broad lockdowns and limitations that started in early 2020.
Major pharmaceutical industries came to a standstill and shifted their attention towards the management of COVID-19, leading to a slump in demand for cold agglutinin disease treatment. Now several research studies have been initiated and companies have again started trial for their respective pipelines. Overall, the impact of the pandemic on the global cold agglutinin disease treatment market is expected to be relatively moderate, with the market continuing to grow steadily due to the ongoing need and research for monoclonal antibodies and other programs to control such kind of disorders.
Key Developments
• On February 4, 2022, Enjaymo (sutimlimab-jome) has received FDA approval to reduce the requirement for red blood cell transfusions in adults having cold agglutinin disease (CAD) related to hemolysis. Enjaymo, the first and only medication for CAD to receive FDA approval, prevents the breakdown of red blood cells (hemolysis).
Competitive Landscape
The major global players in the market include Sanofi, NovelMed Inc., Novartis AG, Swedish Orphan Biovitrum AB, Apellis Pharmaceuticals, Inc., Alpine Immune Sciences, Genentech USA, Inc., Alexion Pharmaceuticals, Inc., Teva Pharmaceuticals USA, Inc. and Viatris Inc. among others.
Why Purchase the Report?
• To visualize the global cold agglutinin disease treatment market segmentation based on type, drug type, route of administration, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of cold agglutinin disease treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global cold agglutinin disease treatment market report would provide approximately 69 tables, 68 figures and 186 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Type
3.2. Snippet by Drug Type
3.3. Snippet by Route of Administration
3.4. Snippet by Distribution Channel
3.5. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Growing development of novel therapies or drugs
4.1.1.2. Rising technological advancements and developments
4.1.2. Restraints
4.1.2.1. Side effects associated with the drugs
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Pricing Analysis
5.6. SWOT Analysis
5.7. Patent Analysis
5.8. Russia-Ukraine War Impact Analysis
5.9. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
7.1.2. Market Attractiveness Index, By Type
7.2. Primary Cold Agglutinin Disease*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Secondary Cold Agglutinin Disease
8. By Drug Type
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
8.1.2. Market Attractiveness Index, By Drug Type
8.2. Biologics*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.2.3. Sutimlimab (Enjaymo)
8.2.4. Rituximab (Rituxan)
8.2.5. Eculizumab (Soliris)
8.3. Purine Analogue
8.3.1. Fludarabine
8.3.2. Azathioprine
8.4. Corticosteroid
8.4.1. Prednisone
8.5. Alkylating Agents
8.5.1. Chlorambucil
8.5.2. Cyclophosphamide
8.6. Folic Acid Supplements
8.7. Others
9. By Route of Administration
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.1.2. Market Attractiveness Index, By Route of Administration
9.2. Oral *
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Parenteral
10. By Distribution Channel
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.1.2. Market Attractiveness Index, By Distribution Channel
10.2. Hospital Pharmacies*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Retail Pharmacies
10.4. Online Pharmacies
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. UK
11.3.7.3. France
11.3.7.4. Italy
11.3.7.5. Spain
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
11.5.7.4. Australia
11.5.7.5. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12. Competitive Landscape
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. Company Profiles
13.1. Sanofi*
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. NovelMed Inc.
13.3. Novartis AG
13.4. Swedish Orphan Biovitrum AB
13.5. Apellis Pharmaceuticals, Inc.
13.6. Alpine Immune Sciences
13.7. Genentech USA, Inc.
13.8. Alexion Pharmaceuticals, Inc.
13.9. Teva Pharmaceuticals USA, Inc.
13.10. Viatris Inc.
LIST NOT EXHAUSTIVE
14. Appendix
14.1. About Us and Services
14.2. Contact Us

언급된 주요 기업들

Sanofi, 4. Key Developments, NovelMed Inc., Novartis AG, Swedish Orphan Biovitrum AB, Apellis Pharmaceuticals, Inc., Alpine Immune Sciences, Genentech USA, Inc., Alexion Pharmaceuticals, Inc., Teva Pharmaceuticals USA, Inc., Viatris Inc.

표 목록 (Tables)

List of Tables

Table 1 Global Cold Agglutinin Disease Treatment Market Value, By Type, 2022, 2026 & 2030 (US$ Million)

Table 2 Global Cold Agglutinin Disease Treatment Market Value, By Drug Type, 2022, 2026 & 2030 (US$ Million)

Table 3 Global Cold Agglutinin Disease Treatment Market Value, By Route of Administration, 2022, 2026 & 2030 (US$ Million)

Table 4 Global Cold Agglutinin Disease Treatment Market Value, By Distribution Channel, 2022, 2026 & 2030 (US$ Million)

Table 5 Global Cold Agglutinin Disease Treatment Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 6 Global Cold Agglutinin Disease Treatment Market Value, By Type, 2022, 2026 & 2030 (US$ Million)

Table 7 Global Cold Agglutinin Disease Treatment Market Value, By Type, 2021-2030 (US$ Million)

Table 8 Global Cold Agglutinin Disease Treatment Market Value, By Drug Type, 2022, 2026 & 2030 (US$ Million)

Table 9 Global Cold Agglutinin Disease Treatment Market Value, By Drug Type, 2021-2030 (US$ Million)

Table 10 Global Cold Agglutinin Disease Treatment Market Value, By Route of Administration, 2022, 2026 & 2030 (US$ Million)

Table 11 Global Cold Agglutinin Disease Treatment Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 12 Global Cold Agglutinin Disease Treatment Market Value, By Distribution Channel, 2022, 2026 & 2030 (US$ Million)

Table 13 Global Cold Agglutinin Disease Treatment Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 14 Global Cold Agglutinin Disease Treatment Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 15 Global Cold Agglutinin Disease Treatment Market Value, By Region, 2021-2030 (US$ Million)

Table 16 North America Cold Agglutinin Disease Treatment Market Value, By Type, 2021-2030 (US$ Million)

Table 17 Global Cold Agglutinin Disease Treatment Market Value, By Drug Type, 2022, 2026 & 2030 (US$ Million)

Table 18 North America Cold Agglutinin Disease Treatment Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 19 North America Cold Agglutinin Disease Treatment Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 20 North America Cold Agglutinin Disease Treatment Market Value, By Country, 2021-2030 (US$ Million)

Table 21 South America Cold Agglutinin Disease Treatment Market Value, By Type, 2021-2030 (US$ Million)

Table 22 South America Cold Agglutinin Disease Treatment Market Value, By Drug Type, 2021-2030 (US$ Million)

Table 23 South America Cold Agglutinin Disease Treatment Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 24 South America Cold Agglutinin Disease Treatment Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 25 South America Cold Agglutinin Disease Treatment Market Value, By Country, 2021-2030 (US$ Million)

Table 26 Europe Cold Agglutinin Disease Treatment Market Value, By Type, 2021-2030 (US$ Million)

Table 27 Europe Cold Agglutinin Disease Treatment Market Value, By Drug Type, 2021-2030 (US$ Million)

Table 28 Europe Cold Agglutinin Disease Treatment Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 29 Europe Cold Agglutinin Disease Treatment Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 30 Europe Cold Agglutinin Disease Treatment Market Value, By Country, 2021-2030 (US$ Million)

Table 31 Asia-Pacific Cold Agglutinin Disease Treatment Market Value, By Type, 2021-2030 (US$ Million)

Table 32 Asia-Pacific Cold Agglutinin Disease Treatment Market Value, By Drug Type, 2021-2030 (US$ Million)

Table 33 Asia-Pacific Cold Agglutinin Disease Treatment Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 34 Asia-Pacific Cold Agglutinin Disease Treatment Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 35 Asia-Pacific Cold Agglutinin Disease Treatment Market Value, By Country, 2021-2030 (US$ Million)

Table 36 Middle East & Africa Cold Agglutinin Disease Treatment Market Value, By Type, 2021-2030 (US$ Million)

Table 37 Middle East & Africa Cold Agglutinin Disease Treatment Market Value, By Drug Type, 2021-2030 (US$ Million)

Table 38 Middle East & Africa Cold Agglutinin Disease Treatment Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 39 Middle East & Africa Cold Agglutinin Disease Treatment Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 40 Sanofi: Overview

Table 41 Sanofi: Product Portfolio

Table 42 Sanofi: Key Developments

Table 43 NovelMed Inc.: Overview

Table 44 NovelMed Inc.: Product Portfolio

Table 45 NovelMed Inc.: Key Developments

Table 46 Novartis AG: Overview

Table 47 Novartis AG: Product Portfolio

Table 48 Novartis AG: Key Developments

Table 49 Swedish Orphan Biovitrum AB: Overview

Table 50 Swedish Orphan Biovitrum AB: Product Portfolio

Table 51 Swedish Orphan Biovitrum AB: Key Developments

Table 52 Apellis Pharmaceuticals, Inc.: Overview

Table 53 Apellis Pharmaceuticals, Inc.: Product Portfolio

Table 54 Apellis Pharmaceuticals, Inc.: Key Developments

Table 55 Alpine Immune Sciences: Overview

Table 56 Alpine Immune Sciences: Product Portfolio

Table 57 Alpine Immune Sciences: Key Developments

Table 58 Genentech USA, Inc.: Overview

Table 59 Genentech USA, Inc.: Product Portfolio

Table 60 Genentech USA, Inc.: Key Developments

Table 61 Alexion Pharmaceuticals, Inc.: Overview

Table 62 Alexion Pharmaceuticals, Inc.: Product Portfolio

Table 63 Alexion Pharmaceuticals, Inc.: Key Developments

Table 64 Teva Pharmaceuticals USA, Inc.: Overview

Table 65 Teva Pharmaceuticals USA, Inc.: Product Portfolio

Table 66 Teva Pharmaceuticals USA, Inc.: Key Developments

Table 67 Viatris Inc.: Overview

Table 68 Viatris Inc.: Product Portfolio

Table 69 Viatris Inc.: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Cold Agglutinin Disease Treatment Market Value, 2021-2030 (US$ Million)

Figure 2 Global Cold Agglutinin Disease Treatment Market Share, By Type, 2022 & 2030 (%)

Figure 3 Global Cold Agglutinin Disease Treatment Market Share, By Drug Type, 2022 & 2030 (%)

Figure 4 Global Cold Agglutinin Disease Treatment Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 5 Global Cold Agglutinin Disease Treatment Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 6 Global Cold Agglutinin Disease Treatment Market Share, By Region, 2022 & 2030 (%)

Figure 7 Global Cold Agglutinin Disease Treatment Market Y-o-Y Growth, By Type, 2022-2030 (%)

Figure 8 Primary Cold Agglutinin Disease Cold Agglutinin Disease Treatment Market Value, 2021-2030 (US$ Million)

Figure 9 Secondary Cold Agglutinin Disease Cold Agglutinin Disease Treatment Market Value, 2021-2030 (US$ Million)

Figure 10 Global Cold Agglutinin Disease Treatment Market Y-o-Y Growth, By Drug Type, 2022-2030 (%)

Figure 11 Biologics Drug Type in Global Cold Agglutinin Disease Treatment Market Value, 2021-2030 (US$ Million)

Figure 12 Purine Analogue Drug Type in Global Cold Agglutinin Disease Treatment Market Value, 2021-2030 (US$ Million)

Figure 13 Corticosteroid Drug Type in Global Cold Agglutinin Disease Treatment Market Value, 2021-2030 (US$ Million)

Figure 14 Alkylating Agents Drug Type in Global Cold Agglutinin Disease Treatment Market Value, 2021-2030 (US$ Million)

Figure 15 Folic Acid Supplements Drug Type in Global Cold Agglutinin Disease Treatment Market Value, 2021-2030 (US$ Million)

Figure 16 Others Drug Type in Global Cold Agglutinin Disease Treatment Market Value, 2021-2030 (US$ Million)

Figure 17 Global Cold Agglutinin Disease Treatment Market Y-o-Y Growth, By Route of Administration, 2022-2030 (%)

Figure 18 Oral Route of Administration in Global Cold Agglutinin Disease Treatment Market Value, 2021-2030 (US$ Million)

Figure 19 Parenteral Route of Administration in Global Cold Agglutinin Disease Treatment Market Value, 2021-2030 (US$ Million)

Figure 20 Global Cold Agglutinin Disease Treatment Market Y-o-Y Growth, By Distribution Channel, 2022-2030 (%)

Figure 21 Hospital Pharmacies Distribution Channel in Global Cold Agglutinin Disease Treatment Market Value, 2021-2030 (US$ Million)

Figure 22 Retail Pharmacies Distribution Channel in Global Cold Agglutinin Disease Treatment Market Value, 2021-2030 (US$ Million)

Figure 23 Others Distribution Channel in Global Cold Agglutinin Disease Treatment Market Value, 2021-2030 (US$ Million)

Figure 24 Global Cold Agglutinin Disease Treatment Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 25 North America Cold Agglutinin Disease Treatment Market Value, 2021-2030 (US$ Million)

Figure 26 Asia-Pacific Cold Agglutinin Disease Treatment Market Value, 2021-2030 (US$ Million)

Figure 27 Europe Cold Agglutinin Disease Treatment Market Value, 2021-2030 (US$ Million)

Figure 28 South America Cold Agglutinin Disease Treatment Market Value, 2021-2030 (US$ Million)

Figure 29 Middle East and Africa Cold Agglutinin Disease Treatment Market Value, 2021-2030 (US$ Million)

Figure 30 North America Cold Agglutinin Disease Treatment Market Value, 2021-2030 (US$ Million)

Figure 31 North America Cold Agglutinin Disease Treatment Market Share, By Type, 2022 & 2030 (%)

Figure 32 North America Cold Agglutinin Disease Treatment Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 33 North America Cold Agglutinin Disease Treatment Market Share, By Drug Type, 2022 & 2030 (%)

Figure 34 North America Cold Agglutinin Disease Treatment Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 35 North America Cold Agglutinin Disease Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 36 South America Cold Agglutinin Disease Treatment Market Value, 2021-2030 (US$ Million)

Figure 37 South America Cold Agglutinin Disease Treatment Market Share, By Type, 2022 & 2030 (%)

Figure 38 South America Cold Agglutinin Disease Treatment Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 39 South America Cold Agglutinin Disease Treatment Market Share, By Drug Type, 2022 & 2030 (%)

Figure 40 South America Cold Agglutinin Disease Treatment Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 41 South America Cold Agglutinin Disease Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 42 Europe Cold Agglutinin Disease Treatment Market Value, 2021-2030 (US$ Million)

Figure 43 Europe Cold Agglutinin Disease Treatment Market Share, By Type, 2022 & 2030 (%)

Figure 44 Europe Cold Agglutinin Disease Treatment Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 45 Europe Cold Agglutinin Disease Treatment Market Share, By Drug Type, 2022 & 2030 (%)

Figure 46 Europe Cold Agglutinin Disease Treatment Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 47 Europe Cold Agglutinin Disease Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 48 Asia-Pacific Cold Agglutinin Disease Treatment Market Value, 2021-2030 (US$ Million)

Figure 49 Asia-Pacific Cold Agglutinin Disease Treatment Market Share, By Type, 2022 & 2030 (%)

Figure 50 Asia-Pacific Cold Agglutinin Disease Treatment Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 51 Asia-Pacific Cold Agglutinin Disease Treatment Market Share, By Drug Type, 2022 & 2030 (%)

Figure 52 Asia-Pacific Cold Agglutinin Disease Treatment Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 53 Asia-Pacific Cold Agglutinin Disease Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 54 Middle East & Africa Cold Agglutinin Disease Treatment Market Value, 2021-2030 (US$ Million)

Figure 55 Middle East & Africa Cold Agglutinin Disease Treatment Market Share, By Type, 2022 & 2030 (%)

Figure 56 Middle East & Africa Cold Agglutinin Disease Treatment Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 57 Middle East & Africa Cold Agglutinin Disease Treatment Market Share, By Drug Type, 2022 & 2030 (%)

Figure 58 Middle East & Africa Cold Agglutinin Disease Treatment Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 59 Sanofi: Financials

Figure 60 NovelMed Inc.: Financials

Figure 61 Novartis AG: Financials

Figure 62 Swedish Orphan Biovitrum AB: Financials

Figure 63 Apellis Pharmaceuticals, Inc.: Financials

Figure 64 Alpine Immune Sciences: Financials

Figure 65 Genentech USA, Inc.: Financials

Figure 66 Alexion Pharmaceuticals, Inc.: Financials

Figure 67 Teva Pharmaceuticals USA, Inc.: Financials

Figure 68 Viatris Inc.: Financials

세계 한랭응집소질환 치료 시장 – 2023-2030

Global Cold Agglutinin Disease Treatment Market - 2023-2030